Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Hypertrophic cardiomyopathy (HCM) occurs in 1 in every 500 individuals. It represents the most common cause of sudden cardiac death in those under the age of twenty-five. 3-5% patients with HCM go on to develop the dilated, hypokinetic end stage (ES) HCM with systolic failure. They have a higher incidence of heart failure, sudden deaths and defibrillator shocks. To the best of our knowledge this is first report of successful use of dronedarone for suppression of VT associated with ES HCM.


S Nanda, V Levin, M W Martinez. Ventricular tachycardia in "end stage" hypertrophic cardiomyopathy: a role of dronedarone. Minerva cardioangiologica. 2012 Dec;60(6):637-42

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 23147440

View Full Text